Cell MedX Corp. (CMXC)
USD 0.43
(N/A%)
USD 0.43
(N/A%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -142.48 Thousand USD | 71.22% |
| 2023 | -495.04 Thousand USD | 31.54% |
| 2022 | -723.06 Thousand USD | 36.52% |
| 2021 | -1.13 Million USD | -2.27% |
| 2020 | -1.11 Million USD | -20.71% |
| 2019 | -922.7 Thousand USD | 40.35% |
| 2018 | -1.54 Million USD | -23.8% |
| 2017 | -1.24 Million USD | 41.59% |
| 2016 | -2.13 Million USD | -107.25% |
| 2015 | -1.03 Million USD | -5471.14% |
| 2014 | -18.52 Thousand USD | -46.62% |
| 2013 | -12.63 Thousand USD | 20.32% |
| 2012 | -15.85 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -142.48 Thousand USD | 71.22% |
| 2024 Q1 | -76.95 Thousand USD | 3.06% |
| 2024 Q2 | -60.54 Thousand USD | 21.32% |
| 2024 Q3 | 119.97 Thousand USD | 298.15% |
| 2024 Q4 | -124.95 Thousand USD | -204.16% |
| 2023 Q1 | -154.68 Thousand USD | 4.84% |
| 2023 FY | -495.04 Thousand USD | 31.54% |
| 2023 Q2 | -155 Thousand USD | -0.21% |
| 2023 Q3 | -118.16 Thousand USD | 23.77% |
| 2023 Q4 | -79.38 Thousand USD | 32.82% |
| 2022 Q1 | -239.35 Thousand USD | 29.87% |
| 2022 FY | -723.06 Thousand USD | 36.52% |
| 2022 Q4 | -162.56 Thousand USD | -28.67% |
| 2022 Q2 | -175.97 Thousand USD | 26.48% |
| 2022 Q3 | -126.33 Thousand USD | 28.21% |
| 2021 Q4 | -341.29 Thousand USD | -90.66% |
| 2021 Q1 | -201.2 Thousand USD | -9.94% |
| 2021 Q2 | -189.33 Thousand USD | 5.9% |
| 2021 FY | -1.13 Million USD | -2.27% |
| 2021 Q3 | -179 Thousand USD | 5.45% |
| 2020 Q2 | -303.48 Thousand USD | -23.73% |
| 2020 Q4 | -183.01 Thousand USD | 49.29% |
| 2020 Q1 | -245.28 Thousand USD | -69.95% |
| 2020 FY | -1.11 Million USD | -20.71% |
| 2020 Q3 | -360.9 Thousand USD | -18.92% |
| 2019 FY | -922.7 Thousand USD | 40.35% |
| 2019 Q4 | -144.33 Thousand USD | 63.05% |
| 2019 Q3 | -390.66 Thousand USD | -206.36% |
| 2019 Q2 | -127.51 Thousand USD | 47.62% |
| 2019 Q1 | -243.46 Thousand USD | -3.02% |
| 2018 Q1 | -833.27 Thousand USD | -311.46% |
| 2018 Q2 | -181.39 Thousand USD | 78.23% |
| 2018 FY | -1.54 Million USD | -23.8% |
| 2018 Q3 | -295.81 Thousand USD | -63.08% |
| 2018 Q4 | -236.32 Thousand USD | 20.11% |
| 2017 Q4 | 394.05 Thousand USD | 229.38% |
| 2017 Q1 | -278.81 Thousand USD | 16.54% |
| 2017 FY | -1.24 Million USD | 41.59% |
| 2017 Q3 | -304.57 Thousand USD | 71.27% |
| 2017 Q2 | -1.06 Million USD | -280.21% |
| 2016 Q3 | -296.01 Thousand USD | 38.28% |
| 2016 FY | -2.13 Million USD | -107.25% |
| 2016 Q4 | -334.08 Thousand USD | -12.86% |
| 2016 Q2 | -479.61 Thousand USD | 53.41% |
| 2016 Q1 | -1.02 Million USD | -252.08% |
| 2015 Q4 | -292.38 Thousand USD | 30.25% |
| 2015 FY | -1.03 Million USD | -5471.14% |
| 2015 Q3 | -419.19 Thousand USD | -53.74% |
| 2015 Q2 | -272.66 Thousand USD | -468.98% |
| 2015 Q1 | -47.92 Thousand USD | -788.93% |
| 2014 FY | -18.52 Thousand USD | -46.62% |
| 2014 Q1 | -5927.00 USD | -295.13% |
| 2014 Q4 | -5391.00 USD | -23.36% |
| 2014 Q2 | -2839.00 USD | 52.1% |
| 2014 Q3 | -4370.00 USD | -53.93% |
| 2013 Q4 | -1500.00 USD | 76.31% |
| 2013 Q2 | -4805.00 USD | 0.0% |
| 2013 FY | -12.63 Thousand USD | 20.32% |
| 2013 Q1 | - USD | 100.0% |
| 2013 Q3 | -6331.00 USD | -31.76% |
| 2012 Q2 | -5882.00 USD | 37.12% |
| 2012 Q3 | -4109.00 USD | 30.14% |
| 2012 Q4 | -2293.00 USD | 44.2% |
| 2012 Q1 | -9354.00 USD | 0.0% |
| 2012 FY | -15.85 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acutus Medical, Inc. | -81.66 Million USD | 99.826% |
| Biotricity, Inc. | -14.09 Million USD | 98.989% |
| Dynatronics Corporation | -2.69 Million USD | 94.718% |
| Nemaura Medical Inc. | -14.14 Million USD | 98.993% |
| PetVivo Holdings, Inc. | -10.95 Million USD | 98.699% |
| RetinalGenix Technologies Inc. | -2.09 Million USD | 93.185% |
| Sonendo, Inc. | -60.91 Million USD | 99.766% |
| Telesis Bio, Inc. | -47.72 Million USD | 99.701% |
| Talis Biomedical Corporation | -62 Million USD | 99.77% |
| Viveve Medical, Inc. | -22.02 Million USD | 99.353% |